Last reviewed · How we verify
CD07223
CD07223 is a small molecule targeting the CD73 enzyme.
CD07223 is a small molecule targeting the CD73 enzyme. Used for Metastatic melanoma.
At a glance
| Generic name | CD07223 |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | CD73 inhibitor |
| Target | CD73 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CD07223 works by inhibiting the CD73 enzyme, which is involved in the production of adenosine. This leads to a decrease in adenosine levels, which in turn reduces inflammation and tumor growth.
Approved indications
- Metastatic melanoma
Common side effects
- Fatigue
Key clinical trials
- Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne (PHASE2)
- Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD07223 CI brief — competitive landscape report
- CD07223 updates RSS · CI watch RSS
- Galderma R&D portfolio CI